BI 765128 / Boehringer Ingelheim - LARVOL DELTA

PARTRIDGE: A Phase 1/2a Study Investigating the Safety and Efficacy of BI 765128 in Patients With Diabetic Macular Ischemia (AAO 2023) - P1/2 | "No dose-limiting or drug-related AEs were reported; there were two ocular AEs. Part B is ongoing."

Clinical • P1/2 data • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

PARTRIDGE: A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (clinicaltrials.gov) - P1/2 | N=46 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Diabetic Retinopathy • Retinal Disorders

PARTRIDGE: A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (clinicaltrials.gov) - P1/2 | N=48 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Diabetic Retinopathy • Retinal Disorders

The Phase I/IIa PARTRIDGE study: Investigating BI 765128 in patients with diabetic macular ischemia (ARVO 2023) - P1/2 | "One aim of the second part is to test whether BI 765128 affects how well people can read letters off a chart. So far, ten people have started the second part, and it is hoped that up to 30 people will participate."

Clinical • P1/2 data • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

PARTRIDGE: A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (clinicaltrials.gov) - P1/2 | N=43 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Diabetic Retinopathy • Retinal Disorders

PARTRIDGE: A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Diabetic Retinopathy • Retinal Disorders

PARTRIDGE: A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (clinicaltrials.gov) - P1/2; N=48; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Feb 2023 ➔ Jun 2023; Trial primary completion date: Feb 2023 ➔ Jun 2023

Clinical • Trial completion date • Trial primary completion date • Diabetic Retinopathy • Retinal Disorders

PARTRIDGE: A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (clinicaltrials.gov) - P1/2; N=48; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Retinopathy • Retinal Disorders

PARTRIDGE: A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (clinicaltrials.gov) - P1/2; N=48; Not yet recruiting; Sponsor: Boehringer Ingelheim

Clinical • New P1/2 trial • Diabetic Retinopathy • Retinal Disorders